Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Deals

GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal

Fineline Cube Nov 7, 2023

GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...

Company Drug

Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy

Fineline Cube Nov 7, 2023

Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...

Company Drug

Clover Biopharmaceuticals Submits Market Filing for Seasonal Influenza Vaccine in Brazil

Fineline Cube Nov 7, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for...

Company Deals

WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares

Fineline Cube Nov 7, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial

Fineline Cube Nov 7, 2023

Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its...

Company Deals Hospital Medical Device

Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery

Fineline Cube Nov 7, 2023

China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic...

Company

Danone Enters China’s Adult FSMP Market with Local Production of Fortimel

Fineline Cube Nov 7, 2023

France-based food company Danone has revealed its strategic plans to enter the adult foods for...

Company Deals

SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China

Fineline Cube Nov 7, 2023

China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with...

Company Drug

RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002

Fineline Cube Nov 7, 2023

RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...

Company Drug

Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China

Fineline Cube Nov 7, 2023

The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted...

Company Deals

Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA

Fineline Cube Nov 7, 2023

Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with...

Company Deals

Takeda Partners with New Horizon Health Technology to Manage Helicobacter pylori in China

Fineline Cube Nov 7, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a...

Company Medical Device

Intuitive Surgical-Fosun Medical Launches Da Vinci Xi Surgical Robot at CIIE

Fineline Cube Nov 7, 2023

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group)...

Company Deals

BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal

Fineline Cube Nov 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...

Company Drug

MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries

Fineline Cube Nov 6, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial...

Company Deals

Baheal Pharmaceutical Partners with AstraZeneca for Exclusive Distribution of Losec in China

Fineline Cube Nov 6, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...

Company Deals

CORXEL Partners with WuXi STA for Sterile Nasal Spray Production

Fineline Cube Nov 6, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...

Company Drug

Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management

Fineline Cube Nov 6, 2023

Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...

Company Drug

Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study

Fineline Cube Nov 6, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Company Drug

AstraZeneca Announces Positive Phase IIb Results for CKD Treatment Combination

Fineline Cube Nov 6, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced last week that its combination therapy of...

Posts pagination

1 … 461 462 463 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.